Why Rare Leukemia Patients Develop Tagraxofusp Resistance: New Study Findings
Researchers at The University of Texas MD Anderson Cancer Center have identified that resistance to tagraxofusp in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) is driven by severe mutations in the TET2 gene and reduced expression of the TXNRD1 enzyme. Published in the journal Leukemia, the study provides a potential framework for using these … Read more